Poor Olfaction Linked to Increased Risk of Parkinson's

This article originally appeared here.
Share this content:
Poor Olfaction Linked to Increased Risk of Parkinson's
Poor Olfaction Linked to Increased Risk of Parkinson's

THURSDAY, Sept. 7, 2017 (HealthDay News) -- Poor olfaction is associated with increased risk of incident Parkinson's disease (PD), according to a study published online Sept. 6 in Neurology.

Honglei Chen, M.D., Ph.D., from the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, and colleagues examined olfaction in relation to incident PD among 1,510 white and 952 black participants of the Health, Aging, and Body Composition study. Olfaction of study participants was assessed with the Brief Smell Identification Test (BSIT) in 1999 to 2000.

The researchers identified a total of 42 incident PD cases, including 30 white and 12 black participants, during an average of 9.8 years of follow-up. Poor sense of smell (indicated by lower BSIT score) correlated with increased risk of PD. The hazard ratio was 1.3 (95 percent confidence interval, 0.5 to 3.6) and 4.8 (95 percent confidence interval, 2 to 11.2) for the second (t2) and lowest (t1) compared with the highest tertile (t3) of BSIT (P trend < 0.00001). In the first five years of follow-up and thereafter, there were significant associations for incident PD (hazard ratios t1/[t2+t3]), 4.2 [95 percent confidence interval, 1.7 to 10.8] and 4.1 [95 percent confidence interval, 1.7 to 9.8]). The association was stronger in white than black participants and for men versus women.

"Poor olfaction predicts PD in short and intermediate terms; the possibility of stronger associations among men and white participants warrants further investigation," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »